Sunshine Biopharma is trading at $2.60, down 5.09%, with no independently corroborated company-specific announcement explaining the November 4 decline.
- A supplied headline described positive Phase 2 cancer-trial results, but the results were not corroborated; available company information identifies SBFM-PL4 as a coronavirus-treatment candidate, not a cancer drug.
- The biotech sector is reported up 2.13%, opposite Sunshine Biopharma’s move.
- Trading volume was not established by the available evidence.